Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Neuroleptic malignant syndrome associated with olanzapine therapy.

Apple JE, Van Hauer G.

Psychosomatics. 1999 May-Jun;40(3):267-8. No abstract available.

PMID:
10341541
2.

[Neuroleptic malignant syndrome associated with olanzapine].

García López MM, Ciprés L, de Cendra E, Vilalta Franch J.

Med Clin (Barc). 1999 Sep 4;113(6):239. Review. Spanish. No abstract available.

PMID:
10472615
3.

Olanzapine induced neuroleptic malignant syndrome--a case review.

Kogoj A, Velikonja I.

Hum Psychopharmacol. 2003 Jun;18(4):301-9. Review.

PMID:
12766935
4.

Neuroleptic malignant syndrome associated with risperidone and olanzapine in first-episode schizophrenia.

Aboraya A, Schumacher J, Abdalla E, LePage J, McGhee M, Butcher D, Griffin H, Shahda M.

W V Med J. 2002 Mar-Apr;98(2):63-5. Review.

PMID:
12048741
5.

Neuroleptic malignant syndrome in an adolescent receiving olanzapine-lithium combination therapy.

Berry N, Pradhan S, Sagar R, Gupta SK.

Pharmacotherapy. 2003 Feb;23(2):255-9. Review.

PMID:
12587815
6.

[Life threatening neuroleptic malignant syndrome due to olanzapine].

Kopf A, Köster J, Schulz A, Krömker H, Becker T.

Psychiatr Prax. 2003 Jul;30(5):279-82. Review. German.

PMID:
12872187
7.

Olanzapine-associated neuroleptic malignant syndrome.

Kontaxakis VP, Havaki-Kontaxaki BJ, Christodoulou NG, Paplos KG.

Prog Neuropsychopharmacol Biol Psychiatry. 2002 Jun;26(5):897-902. Review.

PMID:
12369263
8.

Side effect profiles of new antipsychotic agents.

Casey DE.

J Clin Psychiatry. 1996;57 Suppl 11:40-5; discussion 46-52. Review.

PMID:
8941170
9.

Olanzapine.

Hale AS.

Br J Hosp Med. 1997 Nov 5-18;58(9):442-5. Review.

PMID:
9619205

Supplemental Content

Support Center